Swiss drugmaker Galderma invests $650M in U.S. plants to tap market and avoid tariffs
Galderma, a Swiss dermatology firm, plans to invest over $650 million in U.S. manufacturing through 2030, aiming to strengthen its presence in its fastest-growing market. The company, which generates 40% of its revenue in the U.S., is relocating R&D to Boston and its headquarters to Miami to better compete with rivals like Allergan. CEO Flemming Ørnskov says success in the U.S. is essential, and the investment also serves as a hedge against tariffs.
Galderma’s $650 million commitment through 2030 targets U.S. manufacturing, with its American operations already generating 40% of its $5.24 billion annual revenue. The company is shifting research and development to Boston to access talent, while moving its headquarters to Miami to serve both domestic consumers and Latin American markets. It also maintains a distribution hub in Fort Worth and a presence in Orange County, California, where aesthetic expertise is concentrated. The investment reflects a broader trend of European firms expanding U.S. operations, as foreign direct investment rose by $266 billion to $5.86 trillion by end of 2025, with manufacturing as the largest target.
CEO Flemming Ørnskov frames the move as essential for competing against AbbVie’s Allergan Aesthetics, maker of Botox and Juvéderm. He notes that U.S. regulatory approval for aesthetic products is the strictest globally, yet the market’s importance justifies the effort. The company’s brands include Cetaphil, Alastin, Sculptra, and Restylane, and it faces competition from Sanofi’s Dupixent in dermatology treatments. The investment also serves as a hedge against tariffs, aligning with a wave of European direct investment into American soil.
This investment could reshape competitive dynamics in the U.S. dermatology and aesthetics market, potentially lowering prices or accelerating innovation as Galderma challenges Allergan’s dominance. American consumers may benefit from more product choices and localized supply chains, while U.S. manufacturing and R&D jobs could see growth. However, the shift also signals how tariff threats and market access concerns are driving foreign firms to deepen U.S. roots, which may influence trade policy debates and regional economic development, particularly in Texas, Massachusetts, Florida, and California.